AVCT Avacta Group

Avacta Therapeutics to Present at the 2025 Leerink Global Healthcare Conference

Avacta Therapeutics to Present at the 2025 Leerink Global Healthcare Conference

LONDON and PHILADELPHIA , March 10, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced that the Company will present at the Leerink Global Healthcare Conference on Wednesday, March 12, 2025, at 10:00 a.m. ET in Miami.

A live webcast of the presentation will be available in the investors section of the Company’s website at /investors. The webcast will be archived for at least 30 days following the presentation.

For further information from Avacta, please contact:

Avacta Group plc

Michael Vinegrad, Group Communications

Director
  
Peel Hunt (Nomad and Broker)

James Steel / Chris Golden / Patrick Birkholm



 



Panmure Liberum (Joint Broker)

Emma Earl / Will Goode / Mark Rogers



ICR Healthcare

Mary-Jane Elliott / Jessica Hodgson / Max Bennett
 





Investor Contact

Renee Leck

THRUST Strategic Communications









Media Contact

Carly Scaduto

Carly Scaduto Consulting
 

 

About Avacta 

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.

About the pre|CISION® Platform

The pre|CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION® platform harnesses this tumor specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.



EN
10/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Avacta Group

 PRESS RELEASE

Avacta Therapeutics Announces Presentations at 2025 AACR Annual Meetin...

Avacta Therapeutics Announces Presentations at 2025 AACR Annual Meeting LONDON and PHILADELPHIA, March 26, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced that the Company will have three presentations at the American Association for Cancer Research (AACR) Annual Meeting from April 25-30, 2025 in Chicago, IL. The poster presentations will feature data from the Company’s proprietary pre|CISION® platform and pipeline of...

Franc Gregori ... (+3)
  • Franc Gregori
  • Lala Gregorek
  • Philippa Gardner

Avacta: Executing steadily on therapeutics focused strategy

Avacta continues its transition into a pure-play therapeutics company to advance its pre|CISION-enabled peptide-drug conjugate platform. The expanding pipeline has the potential to improve the therapeutic index of many highly potent yet systemically toxic oncology drugs. Progress has been tangible with early efficacy and safety data from the Phase Ia salivary gland cancer (SGC) dose escalation cohort of lead asset AVA6000 (FAP-Dox), and confirmation of dosing and ongoing enrolment into Phase Ib ...

 PRESS RELEASE

Avacta Therapeutics to Present at the 2025 Leerink Global Healthcare C...

Avacta Therapeutics to Present at the 2025 Leerink Global Healthcare Conference LONDON and PHILADELPHIA , March 10, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced that the Company will present at the Leerink Global Healthcare Conference on Wednesday, March 12, 2025, at 10:00 a.m. ET in Miami. A live webcast of the presentation will be available in the investors section of the Company’s website at /investors. The webcas...

 PRESS RELEASE

Avacta Announces Promising Early Efficacy and Safety Data for AVA6000 ...

Avacta Announces Promising Early Efficacy and Safety Data for AVA6000 in the Phase 1a Dose Escalation and Ongoing Enrollment in the Phase 1b Expansion Cohorts Encouraging Progression Free Survival (PFS) data observed in patients with salivary gland cancers compared to conventional treatments LONDON and PHILADELPHIA, March 07, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, is pleased to announce that the lead program of the Company, AVA...

Brian Moretta ... (+3)
  • Brian Moretta
  • Mark Thomas
  • Martin Hall

Hardman & Co Monthly: January 2025

Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets. Many of the 53 constituents of the index are high-risk, with micro-capitalisations and a long way from pro...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch